Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
IL-23 Inhibitor — Psoriasis / Crohn's

Risankizumab

Brand names: Skyrizi

Risankizumab is a monoclonal antibody biologic given by subcutaneous injection for moderate-to-severe plaque psoriasis and for psoriatic arthritis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively binds the p19 subunit of interleukin-23, inhibiting this cytokine and the downstream Th17 inflammatory pathway central to psoriatic plaque formation.

Prescribing in practice

  • Screen for latent tuberculosis and active infection before starting, and treat latent TB as appropriate before initiation.
  • Avoid live vaccines during treatment and ensure immunisations are up to date beforehand.
  • Given by subcutaneous injection with maintenance dosing every few months after loading doses.

Monitoring

Monitoring is clinical, assessing skin and joint response and reviewing for signs of infection during treatment.

Counselling the patient

  • After the initial doses, maintenance injections are needed only every few months.
  • Report symptoms of infection such as fever or persistent cough.
  • Tell healthcare staff you are on a biologic before having any vaccinations.

Evidence & guidelines

Risankizumab's efficacy in plaque psoriasis was shown in the UltIMMa phase 3 trials, and it is recommended by NICE within its licensed indications.

Reference: IMMvent Trial (Reich et al. Lancet 2019); NICE TA596; SPC Skyrizi; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways